Patterns of Treatment and Clinical Outcomes in Patients With Stage 1/2 EGFR-mutated Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Global, Multicenter, Retrospective Study.
Abstract
Purpose
We report clinical outcomes, mutation testing patterns, and treatment patterns from a global, real-world, retrospective, observational study in patients with stage 1/2 epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Methods
AND MATERIALS Data were extracted from medical records of adults with stage 1/2 EGFR-mutated NSCLC (diagnosed January 2016-December 2019), who underwent stereotactic body radiation therapy (SBRT) as standard of care. The primary objective was assessment of real-world progression-free survival (rwPFS). Secondary objectives included assessment of mutation testing patterns, treatment sequencing post-SBRT, real-world time to next treatment or death (rwTTNTD), and real-world overall survival (rwOS).
Results
Data were extracted from medical records of 82 patients across six countries; 66% of patients had medically inoperable tumors; 43% had tumors harboring exon 19 deletion (Ex19del), 55% had L858R, 1% had both Ex19del and L858R, and 1% had L858R and an exon 20 insertion. Overall, 91% of patients had stage 1A/1B disease and 9% had stage 2A/2B. All patients underwent SBRT as standard of care; 31 patients (38%) progressed following SBRT. Of patients who received subsequent treatment (n = 25), most received EGFR-tyrosine kinase inhibitors (TKIs; 88%; n = 22/25); first-/second-generation EGFR-TKIs n=17, third-generation EGFR-TKIs n=5. Median (95% confidence interval [CI]) rwPFS, rwTTNTD, and rwOS were 47.1 (38.7-57.8), 49.8 (40.7-not estimable [NE]), and 62.9 (50.8-NE) months, respectively. The rwPFS rates at 12, 24, 36, 48, and 60 months (95% CI) were 90% (81-95), 76% (65-84), 65% (53-74), 48% (35-60), and 34% (19-48), respectively.
Conclusions
In this global, real-world, retrospective study in patients with stage 1/2 EGFR-mutated NSCLC who underwent SBRT, the majority of whom had medically inoperable tumors, the 4-year rwPFS rate was <50%. Further studies are needed to confirm the potential role for EGFR-TKI therapy in this setting.